TRIM33 and clinically amyopathic dermatomyositis: Studies comparing LB versus IP have reported conflicting results regarding anti-TIF1-gamma autoantibody sensitivity/specificity with respect to cancer-associated DM (CADM) [1, 6, 7], and there are no studies reporting how well ELISA performs.